Respiratory Syncytial Virus Therapeutics Market Competitive Analysis, Size, Growth Rate, Key Company Share, Outlook by 2027

[Nita Sonwane]

The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.”

Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus...

The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

High Production Scale to Hinder Growth Opportunities in Global Pharmaceutical Space

The COVID-19 contagion is expected to drive the global pharmaceutical industry. Enterprises across the world along with governments from several nations are contributing to the development and distribution of the vaccine. However, the scale at which the production is assumed to take place is a major challenge for most of the renowned players. At Fortune Business Insights™, we are providing actionable insights by closely studying multiple aspects of the current scenario. We are also offering firsthand information on various market trends through our comprehensive research reports.

Mergers and Acquisitions to Help Enterprises Develop Effective Products

The rising adoption of preventive and treatment drugs among children against the disease is expected to drive the growth of the global RSV therapeutics market. In addition, collaborations among key players to develop cost efficient drugs for the treatment of RSV disease is anticipated to increase the demand globally, which is expected to further enhance growth. For instance, in January 2019, Swedish Orphan Biovitrum Ab acquired the distribution rights of Synagis, a respiratory syncytial virus prophylactic drug from AstraZeneca. However, failure of the pipeline drugs in the clinical trials is expected to limit growth.